Enfortumab

Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A) . Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma[1][2].

Product Specifications

CAS Number

[1448664-46-7]

UNSPSC

12352203

Target

ADC Antibody; Nectin-4

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/enfortumab.html

Purity

99.90

Solubility

H2O

Smiles

[Enfortumab]

Molecular Weight

(145.44 kDa)

References & Citations

[1]Challita-Eid PM, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016 May 15;76 (10) :3003-13. |[2]O'Donnell PH, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41 (25) :4107-4117.